Last reviewed · How we verify

Centro Ortopedico y Quirurgico del Pie — Portfolio Competitive Intelligence Brief

Centro Ortopedico y Quirurgico del Pie pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
propanolol propanolol marketed Other
Triclosan 0.5 % Topical Solution Triclosan 0.5 % Topical Solution marketed
Hand antisepsis with Propanolol- 1 60%. Hand antisepsis with Propanolol- 1 60%. marketed Infection Control / Antisepsis (non-standard indication)

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Centro Ortopedico y Quirurgico del Pie:

Cite this brief

Drug Landscape (2026). Centro Ortopedico y Quirurgico del Pie — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centro-ortopedico-y-quirurgico-del-pie. Accessed 2026-05-17.

Related